ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Topical JAK1/2 Inhibitor Pregnancy: Avoid — limited data; systemic ruxolitinib is contraindicated; topical use carries less risk but insufficient safety data

Ruxolitinib Cream

Brand names: Opzelura

Adult dose

Dose: Atopic dermatitis: 1.5% cream applied twice daily to affected areas (max 60 g/week); Vitiligo: 1.5% cream applied twice daily (max 60 g/week)
Route: Topical
Frequency: Twice daily
Max: 60 g cream per week
Atopic dermatitis (mild-moderate, ≥12 years); non-segmental vitiligo (≥12 years) — first licensed treatment for repigmentation in vitiligo; do not apply to face near eyes; apply to actively affected areas only

Paediatric dose

Dose: Same as adult (≥12 years) N/A/kg
Route: Topical
Frequency: Twice daily
Max: 60 g/week
Licensed ≥12 years for both atopic dermatitis and vitiligo

Dose adjustments

Renal

No systemic dose adjustment — topical; avoid large area application in severe renal impairment

Hepatic

No systemic dose adjustment for topical use; limit area if severe hepatic impairment

Paediatric weight-based calculator

Licensed ≥12 years for both atopic dermatitis and vitiligo

Clinical pearls

  • TRuE-V trials (Hamzavi et al. NEJM 2022): ruxolitinib cream achieved facial repigmentation in 30% (F-VASI75) vs 8% placebo at 24 weeks in vitiligo — landmark result as first treatment to demonstrate repigmentation in a randomised trial; MHRA 2023 approved for vitiligo
  • Vitiligo mechanism: JAK-STAT pathway drives CD8+ T-cell-mediated melanocyte destruction via IFN-γ signalling; topical JAK inhibition interrupts this pathway locally, allowing melanocyte survival and repigmentation — novel treatment paradigm
  • TRuE-AD trials: non-inferior to triamcinolone acetonide at 8 weeks in atopic dermatitis; significant advantage — no steroid atrophy, suitable for face/flexures/genitalia where steroids are limited
  • Vitiligo treatment timeline: repigmentation is slow (3-6 months minimum); facial areas respond better than acral (hands, feet); counsel patients on realistic timelines — cessation of treatment typically leads to repigmentation loss
  • MHRA 2023 caution: despite topical route, systemic absorption occurs particularly at high usage or on damaged skin — advise patients not to exceed 60 g/week; MHRA JAK class warnings apply in principle, though risk at topical doses is substantially lower

Contraindications

  • Application to acutely infected skin
  • Known hypersensitivity
  • Avoid on face for vitiligo if near eyelids

Side effects

  • Application site reactions (burning, stinging)
  • Nasopharyngitis
  • Acne at application site
  • Skin atrophy (less than topical steroids)
  • Systemic JAK-related effects at high usage (theoretical at max dose >60 g/week)

Interactions

  • Avoid with other JAK inhibitors (additive systemic exposure if large areas treated)
  • Potent CYP3A4 inhibitors — may increase systemic ruxolitinib exposure at high topical doses

Monitoring

  • Repigmentation response (vitiligo photography at 3-6 months)
  • Eczema control scores (EASI/SCORAD for AD)
  • Application site reactions
  • Signs of secondary skin infection

Reference: BNFc; BNF 90; TRuE-V1 & V2 trials (Hamzavi et al. NEJM 2022); TRuE-AD trials (Kim et al. NEJM 2021); MHRA SPC Opzelura 2023; NICE TA955 (vitiligo, 2024). Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways